ReviewCanadian journal of gastroenterology & hepatology2019
Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations.
Review in Canadian journal of gastroenterology & hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04874428 (Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban and Apixaban in Patients With Compensated Liver Cirrhosis), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban and Apixaban in Patients With Compensated Liver Cirrhosis
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Efficacy and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Liver Disease: a Meta-Analysis and Systematic Review.Cardiovascular drugs and therapy · 2021Pooled it
- Management of Nonmalignant Portal Vein Thrombosis in Cirrhosis.GE Portuguese journal of gastroenterology · 2024Review
- Thrombosis of portal, superior mesenteric, and splenic veins: a case report.Frontiers in pharmacology · 2023Article
- 2020 Clinical Update in Liver Transplantation.Journal of cardiothoracic and vascular anesthesia · 2022Review
- Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward!The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2022Review
- Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry.Frontiers in medicine · 2022Article
- Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis.Clinical and molecular hepatology · 2021Review
- Safety of direct oral anticoagulants in patients with advanced liver disease.Liver international : official journal of the International Association for the Study of the Liver · 2021Article
- A Review of the Incidence Diagnosis and Treatment of Spontaneous Hemorrhage in Patients Treated with Direct Oral Anticoagulants.Journal of clinical medicine · 2020Review
- Recurrent Left Ventricular Thrombus Formation on Rivaroxaban Therapy in Cardiomyopathy and Liver Cirrhosis.JACC. Case reports · 2020Article
- Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review.Advances in therapy · 2020Review
- An algorithmic approach to gastrointestinal bleeding in patients receiving antithrombotic agents.Gastroenterology and hepatology from bed to bench · 2020Review
- Fatal Nonvariceal Gastrointestinal Bleeding in a Cirrhotic Patient Taking Apixaban with No History of Hemorrhage.Cureus · 2019Article
- Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate.World journal of gastroenterology · 2019Review
- Anticoagulation in patients with atrial fibrillation and liver cirrhosis.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of Direct Oral Anticoagulants (DOACs) to the pharmaceutical market provided patients and clinicians with novel convenient and safe options of anticoagulation. The use of this class of medications is currently limited to venous thromboembolic therapy and prophylaxis, in addition to stroke prophylaxis in patients with nonvalvular atrial fibrillation. Despite their altered hemostasis, patients with cirrhosis are thought to be in a procoagulant state and thus prone to thrombus formation. Patients with cirrhosis might benefit from the convenience of DOACs; however, the medical literature includes limited data on the efficacy and safety of DOACs in this special patient population. The aim of this review is to summarize the current evidence for anticoagulation options in patients with cirrhosis and their safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.